LAIs outperform oral antipsychotics in preventing relapse and hospitalization through better adherence and visible nonadherence tracking. Clinician hesitation stems from needle discomfort and misconceptions that injectables reduce patient autonomy, when they actually enhance it.
Prescriber Bias, Not Patient Preference, Limits Long-Acting Antipsychotic Use
We're giving patients autonomy by having them function better
Mark
So if the evidence is this clear, why are we even having this conversation? Why isn't everyone using LAIs?
Mimi
Because doctors are people. Some are uncomfortable with needles. Some genuinely believe they're taking autonomy away, even though the opposite is true.
Luke
But wait—how much of that is real hesitation versus how much is just inertia? We know oral antipsychotics are the default. Is it prescriber discomfort or just that nobody's pushing hard enough to change the habit?
Mimi
Correll's point is that it's the discomfort that prevents the push. If you're uncomfortable, you don't educate. You don't offer the choice.
Mark
And the evidence really does show LAIs prevent relapse better?
Mimi
Yes. Better adherence, visible nonadherence, better outcomes. The meta-analyses are solid.
Luke
But here's what I want to know: in those states where 22 percent of patients get LAIs, what are those prescribers doing differently? Is there data on that?
Mimi
Correll didn't provide that detail. He identified the problem—prescriber attitudes—but the source material doesn't show us what the solution looks like in practice.
Mark
So the next question is: how do you change a prescriber's comfort level?
Luke
Exactly. And that's not answered here. We know the barrier exists. We don't know how to move it.
Mimi
Fair. But naming the barrier is the first step. For years, people blamed patients for not wanting injectables. Correll is saying: that's not the story.
O Pulso
- LAI use in schizophrenia ranges from under 5% to 22% across U.S. states
- LAIs outperform oral antipsychotics in preventing relapse and hospitalization
- Prescriber discomfort, not patient preference, drives low LAI adoption rates
LAIs outperform oral antipsychotics in preventing relapse and hospitalization through better adherence and visible nonadherence tracking. Clinician hesitation stems from needle discomfort and misconceptions that injectables reduce patient autonomy, when they actually enhance it.
Dr. Christoph Correll argues prescriber discomfort, not patient factors, limits long-acting injectable antipsychotic use in schizophrenia, urging clinicians to present injectables as enabling patient autonomy and stability.
At a psychiatry conference in Jersey City, Christoph U. Correll, a professor of psychiatry at Hofstra/Northwell and chair of child and adolescent psychiatry at Charité Universitätsmedizin Berlin, made a straightforward claim: the reason long-acting injectable antipsychotics remain underused in schizophrenia treatment has almost nothing to do with what patients want or need. The barrier, he argued, lives entirely on the prescriber side of the desk.
The evidence for LAIs is robust. Across randomized trials, cohort studies, and meta-analyses, these injectables outperform oral antipsychotics at preventing relapse and hospitalization. The mechanism is simple: better adherence, and the visibility that comes when a patient misses a dose. When someone stays stable, they function better. They can work toward their own goals. The clinical case is settled.
Yet clinicians hesitate. Some are uncomfortable with needles or with administering injections themselves. Others harbor a deeper worry: that offering an LAI sends the message to a patient that they cannot be trusted, that the doctor is taking away their autonomy. This framing, Correll said, gets the story backwards. "We're giving patients autonomy by having them function better and not have to be ambivalent every day," he said. The daily calculus of whether to take a pill can poison relationships with family and caregivers, who may never know if a dose was actually taken. An injection removes that daily negotiation. It removes the ambivalence. It creates space for stability.
Clinicians also worry that once an LAI is administered, the dose cannot be adjusted. Correll addressed this directly: establish the effective oral dose first, then transition to the injectable. The concern dissolves. There is also evidence that tolerability may actually be better with injectables, since they produce less of the peak-and-trough variation that comes with daily oral dosing.
The real measure of prescriber influence emerges in the numbers. Across the United States, the percentage of patients with schizophrenia receiving an LAI ranges from under 5 percent in some states to 22 percent in others. The patients are identical. The illness is the same. The evidence is the same. What differs is whether prescribers feel comfortable offering the choice and whether they follow through with the education patients need to understand it. That variation—a fourfold difference in treatment rates across identical populations—points to a single source: the attitudes and comfort level of the doctors writing the prescriptions.
Citações Notáveis
We're giving patients autonomy by having them function better and not have to be ambivalent every day.— Christoph U. Correll, MD
Quer a matéria completa?
Leia o original em Psychiatric Times ↗